ストックスクリーナーアプリを入手
15.44
2.70%
-0.4278
アフターアワーズ：
15.44
-0.000100
-0.00%
Pieris Pharmaceuticals Inc (PIRS) 最新ニュース
Comparing Evelo Biosciences (NASDAQ:EVLO) and Pieris Pharmaceuticals (NASDAQ:PIRS) - Defense World
How To Trade (PIRS) - Stock Traders Daily
Lynx1 Capital Management LP Adjusts Stake in Pieris Pharmaceuticals Inc - GuruFocus.com
Pieris Pharmaceuticals: Q3 Earnings Snapshot - The Washington Post
Pieris Pharmaceuticals (NASDAQ:PIRS) Stock Rating Upgraded by StockNews.com - Defense World
(PIRS) Investment Analysis and Advice - Stock Traders Daily
Pieris Pharmaceuticals: Q2 Earnings Snapshot - Barchart
Pieris Pharmaceuticals director buys series F preferred stock for $1 By Investing.com - Investing.com South Africa
Pieris Pharmaceuticals director buys series F preferred stock for $1 - Investing.com
(PIRS) Technical Data - Stock Traders Daily
pieris pharmaceuticals, inc. Earnings dates - RTTNews
Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer - The Manila Times
Learn to Evaluate (PIRS) using the Charts - Stock Traders Daily
(PIRS) Trading Signals - Stock Traders Daily
Palvella Therapeutics Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial in Microcystic Lymphatic Malformations - GlobeNewswire
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Sees Significant Decrease in Short Interest - Defense World
New Alzheimer’s Therapy Shows Remarkable Results in Animal Trials - SciTechDaily
How the (PIRS) price action is used to our Advantage - Stock Traders Daily
PIRS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pieris Pharmaceuticals, Inc. Is Fair to Shareholders - Business Wire
Wayne-based Palvella Therapeutics Poised to Go Public Later This Year - VISTA.Today
Pieris Pharmaceuticals Second Quarter 2024 Earnings: US$2.76 loss per share (vs US$3.63 profit in 2Q 2023) - Yahoo Finance
We're A Little Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate - Yahoo Finance
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AFBI, ENV, PIRS, BALY on Behalf of Shareholders - GlobeNewswire
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Pieris Pharmaceuticals, Inc.PIRS - PR Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates K and PIRS on Behalf of Shareholders - ForexTV.com
STOCKHOLDER ALERT: The M&A Class Action Firm Investigates the Mergers of PIRS, ENV, GVP - AccessWire
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Merger of Pieris Pharmaceuticals, Inc. – PIRS - ForexTV.com
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Major Shareholder Adar1 Capital Management, Llc Purchases 3,000 Shares of Stock - Defense World
Adar1 capital management buys $92k worth of Pieris Pharmaceuticals stock - Investing.com
(PIRS) Long Term Investment Analysis - Stock Traders Daily
Pieris Pharmaceuticals (NASDAQ:PIRS) Stock Price Passes Above 50 Day Moving Average of $10.02 - Defense World
Global Chemotherapy Induced Anemia Drug Market 2024 Analysis by Top Key Players |SBI Pharmaceuticals Co. Ltd. - The NRI News
Public Equity Report: Palvella lands on NASDAQ via Pieris merger - BioCentury
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PIRS, EMLD, ACNB, GLXZ on Behalf of Shareholders - The Malaysian Reserve
General Mills, Inc. [GIS] gain 0.57% so far this year. What now? - The DBT News
Finansavisen - Finansavisen
PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc.PIRS - Business Wire
Viking Therapeutics stock (VKTX) could hit all time high and here’s why - BP Journal
Pieris Pharmaceuticals ($PIRS) and Palvella Therapeutics Announce Exciting Merger - BP Journal
Is today’s surge in Dermata Therapeutics (DRMA) justified ? - BP Journal
Shareholder Alert: Ademi LLP investigates whether Pieris Pharmaceuticals, Inc. has obtained a Fair Price for its Public Shareholders - PR Newswire
Crude Oil Gains 1%; AT&T Shares Rise After Q2 Earnings - Benzinga
PIRS Stock on the Rise: A Promising Investment - The InvestChronicle
Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session - Benzinga
Dow Tumbles 300 Points; Tesla Shares Plunge After Q2 Results - Benzinga
Why Is Pieris Pharmaceuticals (PIRS) Stock Up 77% Today? - InvestorPlace
Ivey Business School Opens the Market to celebrate Women in Asset Management Program - The Bubble
Palvella and Pieris to merge - The Pharma Letter
Pieris Pharma stock surges on merger deal (NASDAQ:PIRS) - Seeking Alpha
Pieris Pharmaceuticals (NASDAQ:PIRS) Stock Price Crosses Below 50 Day Moving Average of $9.25 - Defense World
Pieris Pharma Shares Double on Buyout Offer From Palvella Therapeutics - MarketWatch
3.66%
1.11%
大文字化:
|
ボリューム (24 時間):